Skip to main content
Premium Trial:

Request an Annual Quote

New York Grants Conditional OK for CombiMatrix Chromosomal Microarray Test for Miscarriage Analysis

NEW YORK (GenomeWeb News) – CombiMatrix said today that its chromosomal microarray test for miscarriage analysis has received conditional approval from the New York State's Department of Health, allowing the company to begin testing patient samples from the state.

"Gaining the conditional license and ultimately the final approval to market and sell our [Product of Conception] test throughout New York is an important milestone for us that will allow us to broaden the market for our number one growth product," CEO Mark McDonough said in a statement.

"As approved under the conditional license, we will now begin to sell directly to customers and to seek distribution partnerships to leverage our internal sales force. This could be a tremendous opportunity for us and, we believe, for the physicians and patients in New York," he added.

The POC test is the Irvine, Calif.-based firm's fastest growing test based on volume, and following the publication of a study in the New England Journal of Medicine in December indicating chromosomal microarrays can provide more clinically relevant information than traditional karyotyping, as reported by BioArray News, sales of the firm's two chromosomal microarray analysis tests have increased "significantly," CombiMatrix said recently.

The announcement follows a deal last week under which Pathology selected CombiMatrix to be the exclusive provider of Pathology's chromosomal microarray tests for the POC testing market in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.